Having demonstrated anti-tumor activity for HER3-VIA in parental breast cancer cells lines, we extended our work to evaluate whether anti-tumor activity could be demonstrated against resistant variants, specifically tumor cells resistant to HER2-targeting therapies. Here, ERBB3 is linked to breast carcinoma.